GlaxoSmithKline, Collegeville, PA, USA
www.gsk.com/about-us

GSK3882347 – FiMH antagonist
NON-TRADITIONAL ANTI-VIRULENCE
Prevention/treatment of UTIs caused by E.coli

GSK’s orally bioavailable small molecule drug, GSK3882347, targets an adhesive protein found on the surface of E. coli bacteria called FimH. Binding of GSK3882347 to FimH prevents E. coli from binding to the bladder wall, thereby preventing infection. With CARB-X support, the project aims to explore the safety, tolerability and pharmacokinetics of the FimH antagonist in a First Time in Human study which was initiated in September 2020 and is planned to be completed in 2021; and the support also facilitates scale-up of the drug for future clinical and non-clinical studies. UTIs are among the most frequent bacterial infections. UTIs occur when bacteria from the skin or periurethral area enter the urethra and infect the urinary tract and bladder. Most while uncomfortable are relatively easy to treat, however, if drug-resistant bacteria enter the blood stream, they can cause severe complications, including septicaemia, shock and death.

Current Development Stage: Phase 1

CARB-X Investment: Initial investment of up to $7.51m.

Initial CARB-X Investment Date: May 1, 2020

Graduation Date: March 16, 2022